Fintel reports that on July 8, 2025, Scotiabank downgraded their outlook for Sage Therapeutics (NasdaqGM:SAGE) from Sector ...

A month has gone by since the last earnings report for Sage Therapeutics, Inc. (SAGE). Shares have lost about 11.1% in that time frame, underperforming the S&P 500. Will the recent negative trend ...

Sage Therapeutics (NASDAQ:SAGE) will release its quarterly earnings report on Tuesday, 2025-04-29. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Sage ...

Sage Therapeutics, Inc. SAGE is focused on developing life-changing brain health medicines. In July, Sage Therapeutics and partner Biogen BIIB announced top-line data from the phase II KINETIC 2 ...

After the FDA rejection of Zurzuvae in one type of depression and the triple failure of neuro asset dalzanemdor, Sage was ...

Sage Therapeutics (SAGE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Sage Therapeutics Inc.'s stock (SAGE) fell 2.4% Wednesday, headed for a fresh all-time low after the company said it would cease developing a treatment for cognitive impairment associated with ...

Zinger Key Points. Sage Therapeutics to lay off 165+ employees, roughly 33% of workforce, by Q4 2024. Company halts SAGE-324 and dalzanemdor trials after disappointing results.

A Cambridge biotech company is preparing to lay off its entire staff of more than 300 after being acquired by another firm.

Douglas Tsao, an analyst from H.C. Wainwright, reiterated the Hold rating on SAGE Therapeutics (SAGE – Research Report). The associated price target remains the same with $25.00. Douglas Tsao ...

Cambridge biotech firm Sage Therapeutics is laying off most of its employees after announcing its planned acquisition earlier this month.. Sage will cut 338 jobs effective Aug. 22, according to ...